0001493152-21-005951.txt : 20210315 0001493152-21-005951.hdr.sgml : 20210315 20210315080016 ACCESSION NUMBER: 0001493152-21-005951 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210315 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210315 DATE AS OF CHANGE: 20210315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 21739864 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 8-K 1 form8-k.htm
0000764195 false VBI Vaccines Inc/BC 0000764195 2021-03-15 2021-03-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 15, 2021

 

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   001-37769   N/A

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

222 Third Street, Suite 2241

Cambridge, Massachusetts

   02142
(Address of principal executive offices)   (Zip Code)

 

(617) 830-3031

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Shares, no par value per share   VBIV   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On March 15, 2021, VBI Vaccines Inc. (the “Company”) issued a press release announcing that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 10:40 AM ET. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

The Company undertakes no obligation to update, supplement or amend the materials attached hereto.

 

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished pursuant to Item 7.01 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated March 15, 2021 (furnished pursuant to Item 7.01)
104   Cover Page Interactive Data File (formatted as Inline XBRL)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VBI Vaccines Inc.
     
Date: March 15, 2021 By: /s/ Jeff Baxter
    Jeff Baxter
    President and Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference

 

CAMBRIDGE, Mass. (March 15, 2021) – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17 at 10:40 AM ET.

 

Presentation Details:

 

  - Event: Oppenheimer 31st Annual Healthcare Conference
  - Presenters: Jeff Baxter, President and CEO, and David E. Anderson, Ph.D., Chief Scientific Officer
  - Date: Wednesday, March 17, 2021
  - Time: 10:40 – 11:10 AM ET
  - Webcast: https://wsw.com/webcast/oppenheimer9/vbiv/2737603

 

A recording of the webcast will be available on the “Events and Presentations” page of the Company’s website: https://www.vbivaccines.com/investors/events-and-presentations/.

 

About VBI Vaccines Inc.

 

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

 

Website Home: http://www.vbivaccines.com/

News and Resources: http://www.vbivaccines.com/news-and-resources/

Investors: http://www.vbivaccines.com/investors/

 

Cautionary Statement on Forward-looking Information

 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

 

VBI Contact

 

Nicole Anderson

Director, Corporate Communications & IR

Phone: (617) 830-3031 x124

Email: IR@vbivaccines.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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vbiv-20210315.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 vbiv-20210315_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 vbiv-20210315_pre.xml XBRL PRESENTATION FILE XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000764195 2021-03-15 2021-03-15 iso4217:USD shares iso4217:USD shares 0000764195 false VBI Vaccines Inc/BC 8-K 2021-03-15 A1 001-37769 222 Third Street Suite 2241 Cambridge MA 02142 (617) 830-3031 false false false false Common Shares, no par value per share VBIV NASDAQ true true XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Mar. 15, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 15, 2021
Entity File Number 001-37769
Entity Registrant Name VBI Vaccines Inc/BC
Entity Central Index Key 0000764195
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 222 Third Street
Entity Address, Address Line Two Suite 2241
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 830-3031
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol VBIV
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vbivaccines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm vbiv-20210315.xsd vbiv-20210315_lab.xml vbiv-20210315_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "vbiv-20210315_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "vbiv-20210315_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "vbiv-20210315.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2020-03-16/full_ifrs/full_ifrs-cor_2020-03-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "VBIV", "nsuri": "http://vbivaccines.com/20210315", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-03-15to2021-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://vbivaccines.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-03-15to2021-03-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://vbivaccines.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001493152-21-005951-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-005951-xbrl.zip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end